Origimm Biotechnology GmbH

Founded

2012

Staff

Organization type

RDM biotech/pharma

Region

Vienna

Origimm is discovering the origins of the protective immune response to develop breakthrough therapies for the prevention and treatment of acne vulgaris and for preventing infections of medical implants. Both indications are associated with the same bacterium, called Propionibacterium acnes. The development program at Origimm is based on the company’s innovative technology platform ProVaDis.